Rhythm Pharmaceuticals, Inc. RYTM EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s EPS (diluted)?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported EPS (diluted) of -$0.83 in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s EPS (diluted) changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s EPS (diluted) decreased by 2.5% year-over-year, from -$0.81 to -$0.83.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s EPS (diluted) has grown at a 23.0% compound annual growth rate (CAGR), from -$1.36 to -$3.11.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.